Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

DISEASE CHARACTERISTICS: * Diagnosed with advanced hematologic malignancies meeting the following criteria: * Multiple myeloma * Received ≥ 2 lines of prior chemotherapy (induction chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant with or without maintenance therapy is considered one line of therapy) * Acute myeloid leukemia * Acute lymphoblastic leukemia * Diffuse large B-cell lymphoma * Hodgkin lymphoma * Mantle cell lymphoma * Mature T- and NK-cell neoplasms restricted to the following WHO-defined entities: * T-cell prolymphocytic leukemia * T-cell large granular lymphocytic leukemia * Aggressive NK-cell leukemia * Adult T-cell leukemia/lymphoma * Extranodal NK/T-cell lymphoma (nasal type) * Mycosis fungoides * Sézary syndrome * Primary CD30-positive T-cell lymphoproliferative disorders * Primary cutaneous anaplastic large cell lymphoma * Primary cutaneous gamma-delta T-cell lymphoma * Peripheral T-cell lymphoma (not otherwise specified) * Angioimmunoblastic T-cell lymphoma * Anaplastic large cell lymphoma (ALK-positive/ALK-negative) * Grade 3B follicular lymphoma * Relapsed following or progressed during standard therapy * Meeting the following criteria: * Standard intensive therapy is not feasible * Current disease state for which there is no standard effective therapy * Refused standard therapy where no curative option exists * Measurable disease, defined…